All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
DUBLIN – The global product development pipeline for COVID-19 is now twice as big as for any particular cancer indication, a major disease like Alzheimer’s or any other infectious disease indication.
DUBLIN – The biotechnology sector may be more awash with cash now than at any other time in its history. But that does not alter the fundamental dynamic between biotech and big pharma. If anything, their respective roles are becoming better defined, as biotechs learn how to build value into their assets to the point where big pharma is willing to step in and take on the financial risk of scaling a program where it can truly go global.
DUBLIN – The dateline says it all. Everyone and anyone with an interest in European biotechnology were due to assemble in Munich this week, the German biotech hub which was originally chosen to host Bio-Europe Fall 2020. Given the rising numbers of confirmed COVID-19 cases across the globe in recent months, that was never going to happen.
